Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $13.80 Consensus PT from Analysts

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $13.80.

AMRX has been the topic of a number of analyst reports. Barclays assumed coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $15.00 price objective on the stock. Truist Financial set a $15.00 price target on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 7th. Piper Sandler reiterated an “overweight” rating and set a $13.00 price objective (up from $11.00) on shares of Amneal Pharmaceuticals in a research report on Friday, October 31st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Ted C. Nark sold 50,000 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $11.72, for a total value of $586,000.00. Following the completion of the transaction, the director owned 291,029 shares in the company, valued at $3,410,859.88. This represents a 14.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Nikita Shah sold 131,856 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the sale, the executive vice president owned 146,403 shares in the company, valued at $1,745,123.76. This trade represents a 47.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 231,856 shares of company stock valued at $2,743,724. Company insiders own 17.45% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AMRX. Assenagon Asset Management S.A. raised its holdings in Amneal Pharmaceuticals by 75.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock worth $47,398,000 after purchasing an additional 1,611,698 shares in the last quarter. Westshore Wealth LLC bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter worth $13,833,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of Amneal Pharmaceuticals by 1,440.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock valued at $11,790,000 after buying an additional 1,062,045 shares during the period. Rubric Capital Management LP boosted its stake in Amneal Pharmaceuticals by 9.1% during the second quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock valued at $94,737,000 after buying an additional 974,355 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in Amneal Pharmaceuticals by 2,866.0% during the fourth quarter. SG Americas Securities LLC now owns 784,803 shares of the company’s stock worth $9,889,000 after acquiring an additional 758,343 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Down 1.4%

NASDAQ:AMRX opened at $13.39 on Monday. The stock has a 50 day moving average of $12.60 and a 200-day moving average of $10.67. The firm has a market capitalization of $4.21 billion, a PE ratio of 669.83 and a beta of 1.34. Amneal Pharmaceuticals has a 52 week low of $6.68 and a 52 week high of $13.75.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.05. The business had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, analysts predict that Amneal Pharmaceuticals will post 0.53 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.